Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology
- Lexaria, a global innovator in drug delivery platforms, through its patented DehydraTECH(TM) technology, looks to address the growing type 2 diabetes and obesity problem
- Given the success of previous studies, the company is looking to double down on glucagon-like peptide 1 (“GLP-1”) studies for 2024
- GLP-1 treatments are a major player in managing weight and addressing diabetes, and Lexaria’s DehydraTECH(TM) drug delivery platform has the potential of replacing painful and expensive GLP-1 injections with an effective oral delivery path
- The company has already received independent ethics review board approval for its GLP-1 human pilot study #2, a milestone that brings it closer to offering a tolerable oral delivery option for diabetes treatment
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recognizes the tremendous potential in the treatment of type 2 diabetes and obesity, and looks to address it through its patented DehydraTECH(TM) drug delivery technology that offers improved delivery of bioactive compounds. The confidence in its technology, as evidenced by the success of previous clinical studies, has allowed it to double down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. The company is optimistic that the studies will yield positive results, not just in the potential treatment of diabetes but also in weight management, which has been directly linked to diabetes.
According to the Centers for Disease Control and Prevention (“CDC”), more than one in three Americans today are at increased risk for type 2 diabetes. This represents about 98 million Americans, with 81% not knowing they are at such a risk (https://nnw.fm/FMg4v ). Studies showed a massive spike in overall incidences of type 2 diabetes between 2002 and 2018, with one of the main cited risk factors being obesity. The CDC noted that of those diagnosed with the condition, 89.8% of them were overweight or obese, as defined by a body mass index (“BMI”) of 25 kg/m2 or higher. This was further compounded by physical inactivity, with 31.9% of those diagnosed reporting getting less than 10 minutes a week of moderate or vigorous activity (https://nnw.fm/jhDFA).
In March, Lexaria announced details of its upcoming 12-week animal study WEIGHT-A24-1 that will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination (https://nnw.fm/UpfIW ). Results will guide additional human investigations.
The company recently received independent third-party ethics review board approval for its GLP-1 human pilot study #2, seeking to explore the oral delivery of GLP-1 drugs. For Lexaria, this marks a significant milestone that brings it closer to offering a more effective and tolerable oral delivery option for diabetes treatment and weight loss management (https://nnw.fm/57LmL ).
“Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry,” noted Chris Bunka, Lexaria’s CEO.
“I am excited about this study; the Lexaria scientific team believes that a dissolvable oral tablet that delivers an effective fraction of semaglutide along with reduced side effects could potentially offer valuable benefits to the pharmaceutical industry that might lead to a higher likelihood of favorable strategic partnering with leading industry players in GLP-1,” he added.
Previous Lexaria studies have demonstrated that DehydraTECH processing results in higher brain absorption than non-DehydraTECH arms. Already, GLP-1R agonists have been shown to penetrate the brain and activate a subset of GLP-1R-expressing neurons in the arcuate nucleus to produce weight loss. With the upcoming studies, Lexaria looks to evidence that DehydraTECH processing of GLP-1 drugs can enable even faster penetration into brain tissue, ultimately improving overall efficiency in weight loss and blood sugar control. Its management is optimistic that it will replicate the success of previous studies and looks forward to kickstarting the undertaking.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Lexaria, a global innovator in drug delivery platforms, through its patented DehydraTECH(TM) technology, looks to address the growing type 2 diabetes and obesity problem
- Given the success of previous studies, the company is looking to double down on glucagon-like peptide 1 (“GLP-1”) studies for 2024
- GLP-1 treatments are a major player in managing weight and addressing diabetes, and Lexaria’s DehydraTECH(TM) drug delivery platform has the potential of replacing painful and expensive GLP-1 injections with an effective oral delivery path
- The company has already received independent ethics review board approval for its GLP-1 human pilot study #2, a milestone that brings it closer to offering a tolerable oral delivery option for diabetes treatment
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recognizes the tremendous potential in the treatment of type 2 diabetes and obesity, and looks to address it through its patented DehydraTECH(TM) drug delivery technology that offers improved delivery of bioactive compounds. The confidence in its technology, as evidenced by the success of previous clinical studies, has allowed it to double down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. The company is optimistic that the studies will yield positive results, not just in the potential treatment of diabetes but also in weight management, which has been directly linked to diabetes.
According to the Centers for Disease Control and Prevention (“CDC”), more than one in three Americans today are at increased risk for type 2 diabetes. This represents about 98 million Americans, with 81% not knowing they are at such a risk (https://nnw.fm/FMg4v ). Studies showed a massive spike in overall incidences of type 2 diabetes between 2002 and 2018, with one of the main cited risk factors being obesity. The CDC noted that of those diagnosed with the condition, 89.8% of them were overweight or obese, as defined by a body mass index (“BMI”) of 25 kg/m2 or higher. This was further compounded by physical inactivity, with 31.9% of those diagnosed reporting getting less than 10 minutes a week of moderate or vigorous activity (https://nnw.fm/jhDFA).
In March, Lexaria announced details of its upcoming 12-week animal study WEIGHT-A24-1 that will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination (https://nnw.fm/UpfIW ). Results will guide additional human investigations.
The company recently received independent third-party ethics review board approval for its GLP-1 human pilot study #2, seeking to explore the oral delivery of GLP-1 drugs. For Lexaria, this marks a significant milestone that brings it closer to offering a more effective and tolerable oral delivery option for diabetes treatment and weight loss management (https://nnw.fm/57LmL ).
“Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry,” noted Chris Bunka, Lexaria’s CEO.
“I am excited about this study; the Lexaria scientific team believes that a dissolvable oral tablet that delivers an effective fraction of semaglutide along with reduced side effects could potentially offer valuable benefits to the pharmaceutical industry that might lead to a higher likelihood of favorable strategic partnering with leading industry players in GLP-1,” he added.
Previous Lexaria studies have demonstrated that DehydraTECH processing results in higher brain absorption than non-DehydraTECH arms. Already, GLP-1R agonists have been shown to penetrate the brain and activate a subset of GLP-1R-expressing neurons in the arcuate nucleus to produce weight loss. With the upcoming studies, Lexaria looks to evidence that DehydraTECH processing of GLP-1 drugs can enable even faster penetration into brain tissue, ultimately improving overall efficiency in weight loss and blood sugar control. Its management is optimistic that it will replicate the success of previous studies and looks forward to kickstarting the undertaking.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
